Acquisition by Kamal Fariborz of 75000 shares of 4D Molecular subject to Rule 16b-3
| FDMT Stock | USD 4.87 0.26 5.64% |
Slightly above 53% of 4D Molecular's private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding 4D Molecular Therapeutics suggests that some traders are interested. 4D Molecular's investing sentiment can be driven by a variety of factors including economic data, 4D Molecular's earnings reports, geopolitical events, and overall market trends.
FDMT |
Filed transaction by 4d Molecular Therapeutics officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
4D Molecular Fundamental Analysis
We analyze 4D Molecular's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 4D Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 4D Molecular based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
4D Molecular is currently under evaluation in target price category among its peers.
4D Molecular Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 4D Molecular stock to make a market-neutral strategy. Peer analysis of 4D Molecular could also be used in its relative valuation, which is a method of valuing 4D Molecular by comparing valuation metrics with similar companies.
Peers
4D Molecular Related Equities
| GOSS | Gossamer Bio | 4.49 | ||||
| NVCT | Nuvectis Pharma | 2.02 | ||||
| CGEM | Cullinan Oncology | 0.48 | ||||
| STOK | Stoke Therapeutics | 0.19 | ||||
| AKRO | Akero Therapeutics | 0.08 | ||||
| RVMD | Revolution Medicines | 0.36 | ||||
| EWTX | Edgewise Therapeutics | 0.52 | ||||
| BDTX | Black Diamond | 0.80 | ||||
| IPSC | Century Therapeutics | 1.10 | ||||
| REPL | Replimune | 1.16 | ||||
| BMEA | Biomea Fusion | 1.56 | ||||
| PASG | Passage Bio | 1.61 | ||||
| KRON | Kronos Bio | 2.80 | ||||
| MLYS | Mineralys Therapeutics, | 2.83 | ||||
| CCCC | C4 Therapeutics | 2.94 | ||||
| LYRA | Lyra Therapeutics | 5.00 |
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.